- Home
- EPOW vs MEIP Comparison
EPOW vs MEIP Comparison
Compare EPOW & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPOW
- MEIP
- Stock Information
- Founded
- EPOW 2014
- MEIP 2000
- Country
- EPOW China
- MEIP United States
- Employees
- EPOW N/A
- MEIP N/A
- Industry
- EPOW Business Services
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- EPOW Consumer Discretionary
- MEIP Health Care
- Exchange
- EPOW Nasdaq
- MEIP Nasdaq
- Market Cap
- EPOW 20.8M
- MEIP 16.7M
- IPO Year
- EPOW 2021
- MEIP 2003
- Fundamental
- Price
- EPOW $0.79
- MEIP $2.50
- Analyst Decision
- EPOW
- MEIP Hold
- Analyst Count
- EPOW 0
- MEIP 2
- Target Price
- EPOW N/A
- MEIP $7.00
- AVG Volume (30 Days)
- EPOW 33.5K
- MEIP 25.0K
- Earning Date
- EPOW 12-31-2024
- MEIP 02-11-2025
- Dividend Yield
- EPOW N/A
- MEIP N/A
- EPS Growth
- EPOW N/A
- MEIP N/A
- EPS
- EPOW N/A
- MEIP N/A
- Revenue
- EPOW $45,050,405.00
- MEIP N/A
- Revenue This Year
- EPOW N/A
- MEIP N/A
- Revenue Next Year
- EPOW N/A
- MEIP $300.00
- P/E Ratio
- EPOW N/A
- MEIP N/A
- Revenue Growth
- EPOW 18.16
- MEIP 33.76
- 52 Week Low
- EPOW $0.53
- MEIP $2.43
- 52 Week High
- EPOW $1.36
- MEIP $6.39
- Technical
- Relative Strength Index (RSI)
- EPOW 44.43
- MEIP 31.74
- Support Level
- EPOW $0.73
- MEIP $2.43
- Resistance Level
- EPOW $0.82
- MEIP $2.89
- Average True Range (ATR)
- EPOW 0.08
- MEIP 0.11
- MACD
- EPOW -0.00
- MEIP -0.02
- Stochastic Oscillator
- EPOW 21.15
- MEIP 15.22
About EPOW Sunrise New Energy Co. Ltd
Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is into the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.